CAMBRIDGE, MA--(Marketwire - February 19, 2009) - On March 3, the
MIT Enterprise Forum of
Cambridge will feature a keynote address by G. Steven Burrill, CEO of
Burrill & Company. An internationally recognized leader in the
biotechnology industry, Burrill will share insights and analysis on the
future of biotech and how companies can find opportunity in an
ever-changing economic landscape.
Following Burrill's presentation, a panel of experts from both the public
and private sectors will discuss innovative research methods for stem cell
therapies and regenerative medicine. The group will explore regulatory
challenges and policy issues, funding opportunities, perspectives on
commercialization, leading research successfully from the lab to the clinic
and the future of stem cells in diabetes therapy.
Keynote Speaker:
G. Steven Burrill is CEO of
Burrill
& Company, a San Francisco-based global leader in the life sciences
industry focusing on venture capital, private equity, merchant banking and
media. Burrill has received numerous awards and recognitions, including the
BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide
biotech leadership and the 2008 Alan Cranston Living Legend Award by the
Alliance for Aging Research. An internationally recognized spokesman for
the life sciences industry, Burrill has authored a variety of articles and
books and is a highly sought-after public speaker. He currently serves as
chairman of the board at Pharmasset and BioImagene, and sits on the board
of directors at Catalyst Biosciences, DepoMed, Intranasal Therapeutics,
Phytomedics, Proteogenix, Proventys, Targacept and XDx.
Panelists:
Dr. Chad Cowan is a researcher with the Harvard University Department of
Stem Cell and Regenerative Biology and with Massachusetts General Hospital.
Cowan received his B.A. and B.S. degrees with honors, from Kansas
University in 1995 and 1996. He received his Ph.D., from the University of
Texas Southwestern at Dallas. He subsequently completed a postdoctoral
fellowship at Harvard University.
Dr. Richard A. Insel is executive vice president of research for the
Juvenile Diabetes Research Foundation (JDRF). Insel has a distinguished
medical and research career in pediatric immunology and, prior to joining
JDRF in 2003, held various leadership positions at the University of
Rochester Medical Center. Insel was the founding director of the Center for
Human Genetics and Molecular Pediatric Disease and served on the National
Advisory Allergy and Infectious Diseases Council of the National Institutes
of Health.
Dr. Celia M. Witten is director of the office of cellular, tissue and gene
therapy at the U.S. Food and Drug Administration's (FDA) Center for
Biologics Evaluation and Research (CBER). Witten worked for more than 10
years as a practicing physician at the National Rehabilitation Hospital in
Washington, D.C., before joining the FDA as division director of general,
restorative and neurological devices in the Center for Devices and
Radiological Health. Before attending medical school at the University of
Miami, she received a Ph.D. in Mathematics from Stanford University.
The panel will be moderated by Janice T. Bourque, senior vice president and
head of the life sciences group at Comerica Bank. Bourque currently sits on
the board of the MIT Koch Institute for Integrative Cancer Research.
When: Tuesday March 3, 2009
Networking: 5:30 p.m.
Program: 6:15-8:00 p.m.
Reception: 8:00-9:00 p.m.
Where: Stata Center (Bldg. 32), Kirsch Auditorium, 32 Vassar St., Cambridge
Sponsors:
Foley Hoag LLP
Registration and information:
http://www.mitforumcambridge.org/mar.html
Pricing: Forum members: $20; Non-members: $30; The MIT community and
students from all universities, free with college ID.
Contact Information: CONTACT:
Regina Smith
MIT Enterprise Forum of Cambridge
617-253-3937
PRESS CONTACT:
Brad Baker (for MIT Enterprise Forum)
CHEN PR, Inc.
781-672-3118